BIOMAXIMA S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.3 PLN | -4.67% |
|
-5.61% | -12.91% |
| 2023 | BioMaxima S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| 2023 | BioMaxima S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2021 | 79.09M 19.7M 1.57B | Sales 2022 | 144M 35.84M 2.86B | Capitalization | 106M 26.5M 2.11B |
|---|---|---|---|---|---|
| Net income 2021 | 10M 2.49M 199M | Net income 2022 | 28M 6.98M 556M | EV / Sales 2021 | 1.62 x |
| Net Debt 2021 | 14.26M 3.55M 283M | Net cash position 2022 | 7.09M 1.77M 141M | EV / Sales 2022 | 0.69 x |
| P/E ratio 2021 |
11.5
x | P/E ratio 2022 |
3.97
x | Employees | 115 |
| Yield 2021 |
1.71% | Yield 2022 |
1.95% | Free-Float | 65.95% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.67% | ||
| 1 week | -5.61% | ||
| Current month | -4.67% | ||
| 1 month | +0.70% | ||
| 3 months | -7.14% | ||
| 6 months | -13.96% | ||
| Current year | -12.91% |
1 week
13.90
15.00
1 month
13.9016.00
Current year
12.1617.00
1 year
12.1627.15
3 years
12.1640.48
5 years
3.0061.00
10 years
2.8861.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Director of Finance/CFO | 63 | 31/12/01 | |
Piotr Janowski
COO | Chief Operating Officer | - | 16/05/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Miroslaw Panek
BRD | Director/Board Member | 65 | 28/07/21 |
Andrzej Mikosz
BRD | Director/Board Member | - | 30/04/20 |
| Director/Board Member | - | 30/11/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/05/24 | 14.3 | -4.67% | 4,200 |
| 30/04/24 | 15 | +1.01% | 358 |
| 29/04/24 | 14.85 | -1.98% | 456 |
| 26/04/24 | 15.15 | -0.66% | 914 |
Delayed Quote Warsaw S.E., May 02, 2024 at 04:55 pm
More quotes
BioMaxima SA is a Poland-based company active in the laboratory diagnostics sector. It manufactures and distributes reagents and equipment for the laboratory diagnosis. It produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The Company supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -12.91% | 14.92M | |
| -27.79% | 1.36B | |
| -17.62% | 57.84M |
- Stock Market
- Equities
- BMX Stock
